Form 144 | Halozyme Therapeutics(HALO.US) Officer Proposes to Sell 520.4K in Common Stocks

SEC FILLINGS DISCLOSED/ Jun 28, $Halozyme Therapeutics(HALO.US)$ Officer NICOLE LABROSSE intends to sell 10,000 shares of its common stock on Jun 28, with a total market value of approximately $520.4K

Futu NewsJun 29 04:53

Halozyme Therapeutics(HALO.US) Officer Sells US$1.56 Million in Common Stock

$Halozyme Therapeutics(HALO.US)$ Officer LaBrosse Nicole sold 30,000 shares of common stock on Jun 26, 27, 28, 2024 at an average price of $51.931 for a total value of $1.56 million.Source: Announceme

Futu NewsJun 29 04:51

Form 144 | Halozyme Therapeutics(HALO.US) Officer Proposes to Sell 519.34K in Common Stocks

SEC FILLINGS DISCLOSED/ Jun 27, $Halozyme Therapeutics(HALO.US)$ Officer NICOLE LABROSSE intends to sell 10,000 shares of its common stock on Jun 27, with a total market value of approximately $519.34

Futu NewsJun 28 04:36

Form 144 | Halozyme Therapeutics(HALO.US) Officer Proposes to Sell 518.2K in Common Stocks

SEC FILLINGS DISCLOSED/ Jun 26, $Halozyme Therapeutics(HALO.US)$ Officer NICOLE LABROSSE intends to sell 10,000 shares of its common stock on Jun 26, with a total market value of approximately $518.2K

Futu NewsJun 27 04:19

Halozyme Therapeutics Is Maintained at Buy by Benchmark

Halozyme Therapeutics Is Maintained at Buy by Benchmark

Dow JonesJun 25 20:44

Benchmark Co. Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Raises Target Price to $60

Benchmark Co. analyst Robert Wasserman maintains $Halozyme Therapeutics(HALO.US)$ with a buy rating, and adjusts the target price from $50 to $60.According to TipRanks data, the analyst has a success

Futu NewsJun 25 20:31 · Ratings